Unity Biotechnology, Inc., a preclinical biotechnology company, engages in the research and development of therapeutics to extend human health span. The company's lead drug candidates include UBX0101 for musculoskeletal disease with an initial focus on osteoarthritis; and UBX1967 for ophthalmologic diseases. It is also developing programs in pulmonary disorders. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was founded in 2009 and is headquartered in Brisbane, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry N/A
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:UBX
CUSIPN/A
WebN/A
PhoneN/A
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
EmployeesN/A
Outstanding Shares42,310,000
Market Cap$666.46 million
Unity Biotechnology (NASDAQ:UBX) Frequently Asked Questions
What is Unity Biotechnology's stock symbol?
Unity Biotechnology trades on the NASDAQ under the ticker symbol "UBX."
How were Unity Biotechnology's earnings last quarter?
Unity Biotechnology Inc (NASDAQ:UBX) issued its quarterly earnings data on Thursday, June, 7th. The company reported ($4.69) EPS for the quarter, missing the consensus estimate of ($0.33) by $4.36. View Unity Biotechnology's Earnings History.
When is Unity Biotechnology's next earnings date?
What price target have analysts set for UBX?
3 brokerages have issued 12 month price targets for Unity Biotechnology's shares. Their predictions range from $17.00 to $32.00. On average, they anticipate Unity Biotechnology's stock price to reach $24.6667 in the next year. This suggests a possible upside of 55.7% from the stock's current price. View Analyst Price Targets for Unity Biotechnology.
What is the consensus analysts' recommendation for Unity Biotechnology?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Unity Biotechnology in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Unity Biotechnology.
Who are some of Unity Biotechnology's key competitors?
Some companies that are related to Unity Biotechnology include NIHON KOHDEN Co/ADR (NHNKY), BTG (BTGGF), BTG (BTG), Aurora Cannabis (ACBFF), Abcam (ABC), RHOEN-KLINIKUM/ADR (RKAGY), Mallinckrodt (MNK), Select Medical (SEM), HMS (HMSY), Omnicell (OMCL), LifePoint Health (LPNT), MorphoSys (MOR), Halozyme Therapeutics (HALO), Supernus Pharmaceuticals (SUPN) and Global Blood Therapeutics (GBT).
Who are Unity Biotechnology's key executives?
Unity Biotechnology's management team includes the folowing people:
- Mr. Keith R. Leonard Jr., Exec. Chairman & CEO (Age 56)
- Dr. Nathaniel E. David, Co-Founder, Pres & Director (Age 50)
- Dr. Jan M. van Deursen, Founder
- Dr. Judith Campisi Ph.D., Founder
- Mr. Daohong Zhou M.D., Founder
When did Unity Biotechnology IPO?
(UBX) raised $85 million in an initial public offering on Thursday, May 3rd 2018. The company issued 5,000,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, Morgan Stanley and Citigroup acted as the underwriters for the IPO and Mizuho Securities was co-manager.
When does the company's lock-up period expire?
Unity Biotechnology's lock-up period expires on Tuesday, October 30th. Unity Biotechnology had issued 5,000,000 shares in its public offering on May 3rd. The total size of the offering was $85,000,000 based on an initial share price of $17.00. Shares of the company owned by company insiders and major shareholders will be eligible for trade following the expiration of the lock-up period.
Has Unity Biotechnology been receiving favorable news coverage?
News articles about UBX stock have trended somewhat negative recently, according to Accern Sentiment Analysis. Accern identifies positive and negative news coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Unity Biotechnology earned a news and rumor sentiment score of -0.03 on Accern's scale. They also assigned news stories about the company an impact score of 45.24 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the immediate future. View Recent Headlines for Unity Biotechnology.
Who are Unity Biotechnology's major shareholders?
Unity Biotechnology's stock is owned by a number of of institutional and retail investors. Top institutional investors include Baillie Gifford & Co. (8.99%), FMR LLC (8.22%), Partner Fund Management L.P. (1.95%), NF Trinity Capital Hong Kong Ltd (1.44%), Partner Investment Management L.P. (0.73%) and Redmile Group LLC (0.59%).
Which major investors are buying Unity Biotechnology stock?
UBX stock was purchased by a variety of institutional investors in the last quarter, including Baillie Gifford & Co., FMR LLC, Partner Fund Management L.P., NF Trinity Capital Hong Kong Ltd, Partner Investment Management L.P., Redmile Group LLC, BlackRock Inc. and Laurion Capital Management LP.
How do I buy shares of Unity Biotechnology?
Shares of UBX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Unity Biotechnology's stock price today?
One share of UBX stock can currently be purchased for approximately $15.84.
How big of a company is Unity Biotechnology?
Unity Biotechnology has a market capitalization of $666.46 million.
MarketBeat Community Rating for Unity Biotechnology (NASDAQ UBX)
MarketBeat's community ratings are surveys of what our community members think about Unity Biotechnology and other stocks. Vote "Outperform" if you believe UBX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe UBX will underperform the S&P 500 over the long term. You may vote once every thirty days.
